Key takeaways
- 7.55M US adults with psoriasis; 3.0% prevalence, NHANES 2011–2014 (PMID 34190957)
- 19.7% pooled psoriatic arthritis prevalence among psoriasis patients (PMID 29928910)
- 3.6% vs 1.5% psoriasis prevalence in White vs Black US adults (PMID 34190957)
A 7.55M-adult prevalence pool concentrates commercial value in the ~1-in-5 with moderate-to-severe disease and the ~1-in-5 with psoriatic arthritis.
Psoriasis prevalence among US adults is 3.0% (95% CI 2.6–3.4%), or an estimated 7.55 million adults, and has been stable since 2003 (Armstrong et al., NHANES 2011–2014, PMID 34190957). Prevalence is not uniform: it is highest in White adults (3.6%) and lowest in Black adults (1.5%), a gradient that shapes diagnosis rates and access. Plaque psoriasis is the dominant morphology, and disease severity, not headcount, governs where systemic and biologic therapy is used.
Two clinical facts drive commercial concentration. First, only a minority of patients (roughly one in five, per National Psoriasis Foundation estimates) carry moderate-to-severe disease qualifying them for systemic therapy, operationalized in trials as PASI ≥12, body surface area ≥10%, or IGA ≥3 (BE VIVID entry criteria, PMID 33549193). Second, psoriatic arthritis co-occurs in 19.7% of psoriasis patients (pooled; North America 19.5%; Alinaghi et al., PMID 29928910), pulling a large subgroup toward mechanisms with joint efficacy and toward rheumatology co-management. The standard care pathway escalates from topicals and phototherapy through conventional systemics to biologics and oral TYK2 therapy.
The US plaque psoriasis funnel: from a 7.55M-adult prevalence base through severity thresholds to the biologic-eligible segment.
| Segment / measure | Estimate | Basis |
|---|---|---|
| US adults with psoriasis | ~7.55M (3.0% prevalence) | Armstrong et al., NHANES 2011–2014 (PMID 34190957) |
| Prevalence by race (White vs Black) | 3.6% vs 1.5% | Armstrong et al. (PMID 34190957) |
| Moderate-to-severe / systemic-eligible share | ~1 in 5 patients | National Psoriasis Foundation estimate |
| Trial-defining severity threshold | PASI ≥12, BSA ≥10%, IGA ≥3 | BE VIVID entry criteria (PMID 33549193) |
| Psoriatic arthritis comorbidity | 19.7% (North America 19.5%) | Alinaghi et al. meta-analysis (PMID 29928910) |
| Care pathway to biologic/oral therapy | Topicals → phototherapy → conventional systemics → biologics / oral TYK2 | AAD–NPF treatment guidelines |
Sources: Prevalence and demographic figures verified live via PubMed PMID 34190957 (JAMA Dermatology 2021, NHANES 2011–2014). Psoriatic arthritis comorbidity PMID 29928910 (JAAD 2019). Severity thresholds from BE VIVID trial entry criteria PMID 33549193. Moderate-to-severe fraction is a National Psoriasis Foundation clinical estimate (not a single-study figure). Pathway per AAD–NPF guidelines.
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
- Of 7.55 million affected adults, how many are genuinely biologic-eligible today, and how much of that pool is treated? • A prevalence-to-treated funnel from the NHANES base through severity thresholds to biologic initiation
- How does the 19.7% psoriatic arthritis overlap redirect mechanism choice and specialty ownership? • A comorbidity-driven segmentation splitting skin-only from joint-involved patients and the mechanisms each favors
- What does the White-to-Black prevalence gradient imply for underdiagnosis and access equity? • A demographic read on diagnosed-versus-true prevalence and its implications for reach
What's inside
-
1 · Disease Biology: Why Severity, Not Diagnosis Count, Governs Treatment 4 pp
- The stable 3.0% US adult psoriasis prevalence since 2003, per NHANES 2011-2014 data
- Why plaque psoriasis severity, not the raw diagnosed count, determines systemic and biologic therapy use
-
2 · The 7.55-Million Prevalence Pool and the Race-Based Diagnosis Gradient 5 pp
- The 7.55 million US adults with psoriasis (3.0% prevalence, 95% CI 2.6-3.4%), per Armstrong et al.
- The prevalence gradient of 3.6% in White adults versus 1.5% in Black adults, and its implications for diagnosis and access
-
3 · The One-in-Five Who Cross the Moderate-to-Severe Threshold 4 pp
- The roughly 1-in-5 patients with moderate-to-severe disease qualifying for systemic therapy, per National Psoriasis Foundation estimates
- The trial-defining severity thresholds (PASI >=12, BSA >=10%, or IGA >=3) used to identify this population
-
4 · The Psoriatic Arthritis Overlap That Diverts Patients to Rheumatology 4 pp
- The 19.7% pooled psoriatic arthritis prevalence among psoriasis patients (Alinaghi et al., PMID 29928910)
- How joint involvement pulls a large subgroup toward mechanisms with joint efficacy and rheumatology co-management
-
5 · Diagnostic & Severity-Grading Pathway: PASI, BSA and IGA as the Trial-Entry Criteria 5 pp
- How PASI, body surface area, and IGA scoring operationalize the moderate-to-severe threshold used in pivotal trials like BE VIVID
- The standard care pathway escalating from topicals and phototherapy through conventional systemics to biologics
-
6 · The Care-Escalation Funnel: Topicals to Biologics/Oral TYK2 and the Systemic-Eligible Ceiling 3 pp
- The AAD-NPF guideline-driven escalation sequence from topical therapy to biologic and oral TYK2 initiation
- How the systemic-eligible ceiling, roughly one in five patients, caps the addressable biologic and oral-therapy market
Appendix and source ledger included · 45-minute analyst readout included with delivery
Custom assessment delivered in 72 hours.
Assess this reportIncluded with every brief
Get Started
Commission this assessment
AXLRx delivers US Plaque Psoriasis disease landscape built for pharma and biotech commercial, access, and medical affairs teams. Custom assessment in 72 hours.
- 1. Submit your requestUse the intake form to specify your indication, geography, and commercial question.
- 2. Scoping callAXLRx analyst confirms scope, comparators, and delivery format.
- 3. DeliveryResearch-verified assessment in 72 hours with optional analyst readout.
How AXLRx builds this assessment
Prepared by MoatRx analysts on the AXLRx commercial consulting engine.
Every AXLRx assessment is built from primary regulatory sources (FDA, ClinicalTrials.gov), peer-reviewed literature, and live payer policy documentation — not secondary summaries. No secondary summaries, market research reports, or unverified estimates are used. Findings are independently verified before inclusion.
US Plaque Psoriasis Disease Landscape sources: peer-reviewed epidemiology (JAMA Dermatology, JAAD), NHANES, AAD–NPF guidelines, and live policy documentation.
- US adult psoriasis prevalence (3.0%, ~7.55M) verified against PMID 34190957, 'Psoriasis Prevalence in Adults in the United States' (JAMA Dermatology 2021).
- White (3.6%) vs Black (1.5%) prevalence and the 95% CI (2.6–3.4%) read directly from the PMID 34190957 abstract.
- Moderate-to-severe ~20% fraction attributed to a National Psoriasis Foundation clinical estimate, distinct from the single-study NHANES prevalence figure.
Frequently asked questions
Deliverables What formats are included with every assessment?
Every commissioned assessment includes three deliverables: a 20–30 page PDF analyst assessment with verified sources and exhibit tables, an editable Excel model (drug comparison grid, payer formulary data, or patient flow model — depending on deliverable type), and a 10–15 slide PowerPoint readout deck formatted for commercial team presentations. An optional 60-minute analyst readout call is included with all deliveries.
Sources What sources does AXLRx use, and how are findings verified?
AXLRx builds from primary sources only: peer-reviewed dermatology epidemiology, national health survey data, dermatology society guideline documentation, and live coverage policy. No secondary summaries or market research reports. Every factual claim is independently verified before inclusion. Source citations are provided for all key data points in the delivered assessment.
Customisation Can I tailor the assessment to my specific question, geography, or comparator set?
Yes. The intake form captures your indication, target geography, key comparator drugs, and the specific commercial question you need answered. A scoping call confirms scope before research starts. Custom extensions (additional payer markets, pipeline agent profiles, or country-specific deep-dives) can be added to any standard assessment. Commission via the intake form to start.